JP2014158469A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014158469A5 JP2014158469A5 JP2014043403A JP2014043403A JP2014158469A5 JP 2014158469 A5 JP2014158469 A5 JP 2014158469A5 JP 2014043403 A JP2014043403 A JP 2014043403A JP 2014043403 A JP2014043403 A JP 2014043403A JP 2014158469 A5 JP2014158469 A5 JP 2014158469A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- antibody according
- variable region
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 150000001413 amino acids Chemical class 0.000 claims 5
- 101000872077 Homo sapiens Delta-like protein 4 Proteins 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 102000044457 human DLL4 Human genes 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 230000004614 tumor growth Effects 0.000 claims 4
- 108700041286 delta Proteins 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 101100499372 Homo sapiens DLL1 gene Proteins 0.000 claims 1
- 101000928513 Homo sapiens Delta-like protein 3 Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 101100387419 Mus musculus Dll4 gene Proteins 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 102000053255 human DLL3 Human genes 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000004898 n-terminal fragment Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 230000009870 specific binding Effects 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84790406P | 2006-09-29 | 2006-09-29 | |
| US60/847,904 | 2006-09-29 | ||
| US88626007P | 2007-01-23 | 2007-01-23 | |
| US60/886,260 | 2007-01-23 | ||
| US94254207P | 2007-06-07 | 2007-06-07 | |
| US60/942,542 | 2007-06-07 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009530419A Division JP5535633B2 (ja) | 2006-09-29 | 2007-09-28 | 癌の診断および処置のための組成物および方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016164264A Division JP2017002076A (ja) | 2006-09-29 | 2016-08-25 | 癌の診断および処置のための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014158469A JP2014158469A (ja) | 2014-09-04 |
| JP2014158469A5 true JP2014158469A5 (enExample) | 2014-10-16 |
| JP5997194B2 JP5997194B2 (ja) | 2016-09-28 |
Family
ID=39268983
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009530419A Expired - Fee Related JP5535633B2 (ja) | 2006-09-29 | 2007-09-28 | 癌の診断および処置のための組成物および方法 |
| JP2014043403A Expired - Fee Related JP5997194B2 (ja) | 2006-09-29 | 2014-03-06 | 癌の診断および処置のための組成物および方法 |
| JP2016164264A Pending JP2017002076A (ja) | 2006-09-29 | 2016-08-25 | 癌の診断および処置のための組成物および方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009530419A Expired - Fee Related JP5535633B2 (ja) | 2006-09-29 | 2007-09-28 | 癌の診断および処置のための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016164264A Pending JP2017002076A (ja) | 2006-09-29 | 2016-08-25 | 癌の診断および処置のための組成物および方法 |
Country Status (27)
| Country | Link |
|---|---|
| US (5) | US7750124B2 (enExample) |
| EP (3) | EP2562188A3 (enExample) |
| JP (3) | JP5535633B2 (enExample) |
| KR (1) | KR101477824B1 (enExample) |
| AU (1) | AU2007305443B2 (enExample) |
| BR (1) | BRPI0717431A2 (enExample) |
| CA (1) | CA2664738C (enExample) |
| CO (1) | CO6180466A2 (enExample) |
| CR (1) | CR10667A (enExample) |
| CY (1) | CY1117154T1 (enExample) |
| DK (1) | DK2066694T3 (enExample) |
| EA (1) | EA018260B1 (enExample) |
| ES (1) | ES2557953T3 (enExample) |
| HR (1) | HRP20160082T1 (enExample) |
| HU (1) | HUE028379T2 (enExample) |
| IL (1) | IL197721A (enExample) |
| MA (1) | MA30808B1 (enExample) |
| ME (1) | ME02371B (enExample) |
| MX (1) | MX2009003229A (enExample) |
| NO (1) | NO20091635L (enExample) |
| NZ (1) | NZ576404A (enExample) |
| PL (1) | PL2066694T3 (enExample) |
| PT (1) | PT2066694E (enExample) |
| RS (1) | RS54452B1 (enExample) |
| SI (1) | SI2066694T1 (enExample) |
| WO (1) | WO2008042236A2 (enExample) |
| ZA (1) | ZA200901615B (enExample) |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7906116B2 (en) * | 2005-09-01 | 2011-03-15 | Parkash Gill | Methods for using and identifying modulators of Delta-like 4 |
| CA2655362A1 (en) | 2006-06-13 | 2007-12-21 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
| HUE028379T2 (en) | 2006-09-29 | 2016-12-28 | Oncomed Pharm Inc | Preparations and procedures for the diagnosis and treatment of cancer |
| NO347649B1 (no) * | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| AU2008209482B2 (en) | 2007-01-24 | 2014-05-01 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
| WO2008091222A1 (en) * | 2007-01-26 | 2008-07-31 | Bioinvent International Ab | Dll4 signaling inhibitors and uses thereof |
| GB0709333D0 (en) * | 2007-05-15 | 2007-06-20 | Smart Targeting Ltd | Binding protein |
| HRP20151261T1 (hr) | 2007-07-02 | 2016-01-01 | Oncomed Pharmaceuticals, Inc. | Sastavi i postupci za lijeäśenje i dijagnosticiranje raka |
| US8119366B2 (en) | 2007-10-05 | 2012-02-21 | Trojan Technologies, Ltd. | Antennapedia-dominant negative mastermind-like construct |
| CA2722466A1 (en) | 2008-04-29 | 2009-11-05 | Tariq Ghayur | Dual variable domain immunoglobulins and uses thereof |
| CN102112154B (zh) * | 2008-05-30 | 2013-10-30 | 埃克斯生物科技公司 | 白细胞介素-1α抗体及使用方法 |
| SG191639A1 (en) | 2008-06-03 | 2013-07-31 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| EP2297208A4 (en) | 2008-06-03 | 2012-07-11 | Abbott Lab | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES |
| KR20110031369A (ko) | 2008-07-08 | 2011-03-25 | 아보트 러보러터리즈 | 프로스타글란딘 ｅ2 이원 가변 도메인 면역글로불린 및 이의 용도 |
| US8834875B2 (en) | 2010-01-13 | 2014-09-16 | Oncomed Pharmaceuticals, Inc. | Notch1 binding agents and methods of use thereof |
| NZ590127A (en) | 2008-07-08 | 2012-11-30 | Oncomed Pharm Inc | Notch1 receptor binding agents and methods of use thereof |
| US9132189B2 (en) | 2008-07-08 | 2015-09-15 | Oncomed Pharmaceuticals, Inc. | Notch1 binding agents and methods of use thereof |
| US8652843B2 (en) | 2008-08-12 | 2014-02-18 | Oncomed Pharmaceuticals, Inc. | DDR1-binding agents and methods of use thereof |
| EP2344536A1 (en) * | 2008-09-19 | 2011-07-20 | MedImmune, LLC | Antibodies directed to dll4 and uses thereof |
| DK2365828T3 (en) | 2008-11-07 | 2014-12-08 | Galaxy Biotech Llc | Monoclonal antibodies against fibroblast second |
| DK2356270T3 (da) * | 2008-11-07 | 2016-12-12 | Fabrus Llc | Kombinatoriske antistofbiblioteker og anvendelser deraf |
| EP2424567B1 (en) | 2009-04-27 | 2018-11-21 | OncoMed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| TWI513465B (zh) * | 2009-06-25 | 2015-12-21 | Regeneron Pharma | 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法 |
| SG178930A1 (en) | 2009-08-29 | 2012-04-27 | Abbott Lab | Therapeutic dll4 binding proteins |
| RU2012112550A (ru) | 2009-09-01 | 2013-10-10 | Эбботт Лэборетриз | Иммуноглобулины с двумя вариабельными доменами и их применение |
| TW201119676A (en) | 2009-10-15 | 2011-06-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| ES2895226T3 (es) * | 2009-10-16 | 2022-02-18 | Mereo Biopharma 5 Inc | Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensivos |
| UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| WO2011063237A2 (en) | 2009-11-19 | 2011-05-26 | Oncomed Pharmaceuticals, Inc. | Jagged-binding agents and uses thereof |
| WO2011068840A1 (en) * | 2009-12-01 | 2011-06-09 | Oncomed Pharmaceuticals, Inc. | Methods for treating cancers comprising k-ras mutations |
| TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Ｗｎｔ拮抗劑及治療和篩選方法 |
| JO3183B1 (ar) | 2010-01-29 | 2018-03-08 | Regeneron Pharma | طرق لمعالجة أمراض المناعة الذاتية مضادات dll4 |
| CN103237901B (zh) | 2010-03-01 | 2016-08-03 | 卡里斯生命科学瑞士控股有限责任公司 | 用于治疗诊断的生物标志物 |
| RU2605928C2 (ru) * | 2010-03-02 | 2016-12-27 | Эббви Инк. | Терапевтические dll4-связывающие белки |
| WO2011127219A1 (en) | 2010-04-06 | 2011-10-13 | Caris Life Sciences Luxembourg Holdings | Circulating biomarkers for disease |
| EP2601218A4 (en) | 2010-08-03 | 2015-02-18 | Abbvie Inc | VARIABLE DOUBLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF |
| CA2808417A1 (en) * | 2010-08-18 | 2012-02-23 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers for disease |
| BR112013004581A2 (pt) | 2010-08-26 | 2017-06-27 | Abbvie Inc | imunoglobulinas de domínio variável dual e seus usos |
| US8551479B2 (en) | 2010-09-10 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
| US20130323265A1 (en) * | 2010-11-15 | 2013-12-05 | Oncomed Pharmaceuticals, Inc. | Methods for treating cancer with dll4 antagonists |
| WO2012092539A2 (en) | 2010-12-31 | 2012-07-05 | Takeda Pharmaceutical Company Limited | Antibodies to dll4 and uses thereof |
| AU2012235767B2 (en) * | 2011-03-27 | 2016-02-04 | Oncostem Diagnostics (Mauritius) Pvt. Ltd. | Markers for identifying tumor cells, methods and kit thereof |
| WO2012174394A1 (en) * | 2011-06-17 | 2012-12-20 | Harris Adrian L | Methods of enhancing the response to radiation in tumor therapy using anti-dll4 antibodies |
| BR112014000765A2 (pt) | 2011-07-15 | 2017-06-13 | Oncomed Pharm Inc | agentes de ligação a rspo e seus usos |
| US20130108641A1 (en) * | 2011-09-14 | 2013-05-02 | Sanofi | Anti-gitr antibodies |
| PT2758073T (pt) | 2011-09-23 | 2019-02-01 | Oncomed Pharm Inc | Agentes de ligação a vegf/dll4 e utilizações dos mesmos |
| JP2015508994A (ja) | 2011-12-30 | 2015-03-26 | アッヴィ・インコーポレイテッド | Ｉｌ−１３および／またはｉｌ−１７に対する二重可変ドメイン免疫グロブリン |
| WO2014062245A2 (en) * | 2012-05-31 | 2014-04-24 | Sorrento Therapeutics Inc. | Antigen binding proteins that bind dll-4 |
| HK1204950A1 (en) | 2012-06-06 | 2015-12-11 | 昂考梅德药品有限公司 | Binding agents that modulate the hippo pathway and uses thereof |
| MX2015000565A (es) | 2012-07-13 | 2015-04-10 | Oncomed Pharm Inc | Agentes de union de proteina de r-espondina humana (rspo3) y usos de los mismos. |
| KR101935088B1 (ko) | 2012-08-24 | 2019-01-04 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신 |
| EP2906295A4 (en) * | 2012-10-15 | 2016-06-01 | Oncomed Pharm Inc | METHODS OF TREATING OCULAR DISEASES |
| EP2914961A4 (en) * | 2012-10-31 | 2016-04-20 | Oncomed Pharm Inc | METHODS AND MONITORING A TREATMENT BY AN ANTAGONIST OF DLL4 |
| RU2636043C2 (ru) | 2012-11-01 | 2017-11-17 | Эббви Инк. | Анти-vegf/dll4-иммуноглобулины с двойными вариабельными доменами и их применения |
| AR093445A1 (es) | 2012-11-14 | 2015-06-10 | Regeneron Pharma | Metodos para tratar el cancer de ovario con antagonistas de dll4 |
| AU2013355379B2 (en) | 2012-12-04 | 2018-08-09 | Oncomed Pharmaceuticals, Inc. | Immunotherapy with binding agents |
| JP6449537B2 (ja) * | 2012-12-27 | 2019-01-09 | 日本メジフィジックス株式会社 | 抗腫瘍剤、及び、抗腫瘍用キット |
| CN105324396A (zh) | 2013-03-15 | 2016-02-10 | 艾伯维公司 | 针对IL-1β和/或IL-17的双重特异性结合蛋白 |
| GB201312727D0 (en) * | 2013-07-16 | 2013-08-28 | Isis Innovation | Modulators |
| PH12019501393B1 (en) | 2013-08-01 | 2022-09-07 | Five Prime Therapeutics Inc | Afucosylated anti-fgfr2iiib antibodies |
| CA2931975A1 (en) | 2013-12-02 | 2015-06-11 | Oncomed Pharmaceuticals, Inc. | Identification of predictive biomarkers associated with wnt pathway inhibitors |
| WO2015108203A1 (ja) * | 2014-01-15 | 2015-07-23 | 株式会社オーダーメードメディカルリサーチ | 抗ｓｌｃ６ａ６抗体を用いたがん治療用医薬組成物 |
| IL289475B2 (en) * | 2014-07-21 | 2023-10-01 | Delinia Inc | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| JP2017528523A (ja) | 2014-09-16 | 2017-09-28 | オンコメッド ファーマシューティカルズ インコーポレイテッド | 線維性疾患の治療 |
| AU2015338974B2 (en) | 2014-10-31 | 2021-08-26 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
| US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
| TWI715587B (zh) | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Ｔｉｇｉｔ結合劑和彼之用途 |
| TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白 |
| US11339213B2 (en) | 2015-09-23 | 2022-05-24 | Mereo Biopharma 5, Inc. | Methods and compositions for treatment of cancer |
| CN108368174B (zh) | 2015-11-23 | 2023-04-14 | 戊瑞治疗有限公司 | 用于癌症治疗的单独fgfr2抑制剂或与免疫刺激剂的组合 |
| US20170204154A1 (en) * | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| CN114191067B (zh) | 2016-05-19 | 2024-12-17 | 圣安娜技术有限公司 | 具有双囊结构以对组织产生并施加消融区域的导管 |
| US11026996B2 (en) * | 2016-05-25 | 2021-06-08 | The Trustees Of Columbia University In The City Of New York | Human Notch1 based fusion proteins as decoy inhibitors of jagged-notch signaling and DLL-notch signaling |
| IL299099B2 (en) | 2016-06-27 | 2025-07-01 | Univ California | Cancer treatment combinations |
| SG10201913583QA (en) * | 2016-08-23 | 2020-02-27 | Univ California | Proteolytically cleavable chimeric polypeptides and methods of use thereof |
| IL265484B1 (en) | 2016-09-21 | 2025-09-01 | Aptevo Res & Development Llc | Cd123 binding proteins and related compositions and methods |
| JP2019532996A (ja) | 2016-11-08 | 2019-11-14 | デリニア，インコーポレーテッド | 自己免疫疾患を処置するためのｉｌ−２変異体 |
| US11230596B2 (en) | 2016-11-30 | 2022-01-25 | Mereo Biopharma 5, Inc. | Methods for treatment of cancer comprising TIGIT-binding agents |
| BR112019023898A2 (pt) | 2017-05-16 | 2020-06-09 | Five Prime Therapeutics Inc | método para tratamento de câncer gástrico, uso de um anticorpo e composição |
| WO2019232432A1 (en) | 2018-06-01 | 2019-12-05 | Santa Anna Tech Llc | Multi-stage vapor-based ablation treatment methods and vapor generation and delivery systems |
| WO2020056031A1 (en) | 2018-09-11 | 2020-03-19 | Aqua Heart, Inc. | Heated vapor ablation systems and methods for treating cardiac conditions |
| AU2019380595A1 (en) | 2018-11-15 | 2021-06-03 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with VEGF/DLL4 binding agent |
| WO2021041818A1 (en) | 2019-08-28 | 2021-03-04 | Santa Anna Tech Llc | Systems and methods for ablating prostate tissue |
| EP4090276A4 (en) | 2020-01-15 | 2024-05-08 | Aqua Medical, Inc. | STEAM ABLATION SYSTEM WITH SIMPLIFIED STEAM RELEASE CONTROL |
| EP4225180A4 (en) | 2020-10-08 | 2024-10-30 | Santa Anna Tech LLC | VISUALIZATION-CAPABLE ABLATION CATHETERS, SYSTEMS AND PROCEDURES |
| WO2023149977A1 (en) * | 2022-02-04 | 2023-08-10 | Mereo Biopharma 5, Inc. | Methods for treating cancer |
Family Cites Families (131)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| FR2248608B1 (enExample) * | 1973-10-17 | 1977-05-27 | Labo Electronique Physique | |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4588585A (en) | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| CA2089661C (en) | 1990-08-29 | 2007-04-03 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| US6582959B2 (en) | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
| IL101728A (en) | 1991-05-03 | 2007-08-19 | Univ Yale | Human Abandonment and Delta, Restrictive Areas of Effect in Tophoric Proteins, and Methods Based on Them |
| US20050112121A1 (en) * | 1992-04-30 | 2005-05-26 | Yale University | Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids |
| US5786158A (en) | 1992-04-30 | 1998-07-28 | Yale University | Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids |
| US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| ES2334953T3 (es) * | 1995-06-28 | 2010-03-17 | Imperial Cancer Research Technology Limited | Secuencias de nucleotidos y proteinas de genes delta de vertebrados y metodos basados en los mismos. |
| US5730977A (en) | 1995-08-21 | 1998-03-24 | Mitsui Toatsu Chemicals, Inc. | Anti-VEGF human monoclonal antibody |
| JPH09124697A (ja) | 1995-11-01 | 1997-05-13 | Toagosei Co Ltd | ペプチド及びモノクローナル抗体 |
| US6337387B1 (en) | 1995-11-17 | 2002-01-08 | Asahi Kasei Kabushiki Kaisha | Differentiation-suppressive polypeptide |
| US20020137890A1 (en) * | 1997-03-31 | 2002-09-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US20060122373A1 (en) * | 1997-04-04 | 2006-06-08 | Millennium Pharmaceuticals, Inc. | Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof |
| ATE342358T1 (de) | 1997-04-04 | 2006-11-15 | Millennium Biotherapeutics Inc | Neue menschliche delta3-zusammensetzung und deren therapeutische und diagnostische verwendungen |
| US6121045A (en) * | 1997-04-04 | 2000-09-19 | Millennium Biotherapeutics, Inc. | Human Delta3 nucleic acid molecules |
| US20030180784A1 (en) * | 1997-04-04 | 2003-09-25 | Millennium Pharmaceuticals, Inc. | Novel human Delta3 compositions and therapeutic and diagnostic uses therefor |
| DK1325932T5 (da) | 1997-04-07 | 2005-10-03 | Genentech Inc | Anti-VEGF antistoffer |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| US20070059302A1 (en) | 1997-04-07 | 2007-03-15 | Genentech, Inc. | Anti-vegf antibodies |
| EP0977853A1 (en) | 1997-04-25 | 2000-02-09 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
| US7951917B1 (en) | 1997-05-02 | 2011-05-31 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| AU751659B2 (en) | 1997-05-02 | 2002-08-22 | Genentech Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| DE69837601T2 (de) * | 1997-05-14 | 2007-12-27 | Asahi Kasei Kabushiki Kaisha | Neuer hemmer der differentierung |
| WO1998057621A1 (en) | 1997-06-18 | 1998-12-23 | The Trustees Of Columbia University In The City Ofnew York | Angiogenic modulation by notch signal transduction |
| US6004528A (en) * | 1997-09-18 | 1999-12-21 | Bergstein; Ivan | Methods of cancer diagnosis and therapy targeted against the cancer stemline |
| JP2002523018A (ja) | 1998-07-27 | 2002-07-30 | アムジエン・インコーポレーテツド | デルタ関連ポリペプチド |
| CA2372053C (en) | 1999-04-28 | 2008-09-02 | Board Of Regents, The University Of Texas System | Compositions and methods for cancer treatment by selectively inhibiting vegf |
| HU230159B1 (hu) | 1999-06-08 | 2015-09-28 | Regeneron Pharmaceuticals, Inc. | VEGF receptor kimérák alkalmazása vaszkuláris permeabilitással jellemzett szembetegség kezelésére |
| JP2003505082A (ja) | 1999-07-26 | 2003-02-12 | ジェネンテック・インコーポレーテッド | 新規なポリヌクレオチドとその使用法 |
| EP1250426A2 (en) | 1999-12-01 | 2002-10-23 | Genentech Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding same |
| WO2001077169A2 (en) | 2000-04-05 | 2001-10-18 | Kirin Beer Kabushiki Kaisha | Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides |
| US20110131679A2 (en) | 2000-04-19 | 2011-06-02 | Thomas La Rosa | Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement |
| GB0014185D0 (en) * | 2000-06-09 | 2000-08-02 | Novartis Res Found | Compound and method |
| US20020028488A1 (en) * | 2000-06-19 | 2002-03-07 | Sujay Singh | Transgenic avian species for making human and chimeric antibodies |
| US6984522B2 (en) | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
| US6689744B2 (en) * | 2000-09-22 | 2004-02-10 | Genentech, Inc. | Notch receptor agonists and uses |
| US7667004B2 (en) | 2001-04-17 | 2010-02-23 | Abmaxis, Inc. | Humanized antibodies against vascular endothelial growth factor |
| EP1409005A1 (en) * | 2001-07-25 | 2004-04-21 | Lorantis Limited | Modulators of notch signalling for use in immunotherapy |
| WO2003012105A2 (en) | 2001-08-01 | 2003-02-13 | University Of Bristol | Vegf isoform |
| EP1446424A2 (en) * | 2001-11-14 | 2004-08-18 | Lorantis Limited | Composition comprising inhibitors of the notch signalling pathway for the modulation of the immune system |
| WO2003042246A2 (en) * | 2001-11-14 | 2003-05-22 | Lorantis Limited | Inhibitors of the notch signalling pathway for use in the treatment of cancer |
| US20050137130A1 (en) * | 2001-11-14 | 2005-06-23 | Bodmer Mark W. | Medical treatment |
| CA2469204A1 (en) * | 2001-12-07 | 2003-06-19 | Regents Of The University Of Michigan | Prospective identification and characterization of breast cancer stem cells |
| US8034904B2 (en) | 2002-06-14 | 2011-10-11 | Immunogen Inc. | Anti-IGF-I receptor antibody |
| GB0218879D0 (en) * | 2002-08-14 | 2002-09-25 | Lorantis Ltd | Medical treatment |
| AU2003267563A1 (en) * | 2002-09-10 | 2004-04-30 | Lorantis Limited | Pharmaceutical composition and medical treatments comprising notch ligand proteins |
| AU2004247095A1 (en) | 2003-06-06 | 2004-12-23 | Regeneron Pharmaceuticals, Inc. | Use of VEGF inhibitors for tumor regression |
| US7758859B2 (en) | 2003-08-01 | 2010-07-20 | Genentech, Inc. | Anti-VEGF antibodies |
| US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| CA2534898A1 (en) | 2003-08-08 | 2005-02-17 | Immunomedics, Inc. | Bispecific antibodies for inducing apoptosis of tumor and diseased cells |
| FR2859725B1 (fr) | 2003-09-16 | 2006-03-10 | Neovacs | Procede a haut rendement pour l'obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine |
| AU2005254058A1 (en) | 2004-06-10 | 2005-12-29 | Regeneron Pharmaceuticals, Inc. | Use of VEGF inhibitors for the treatment of human cancer |
| JP2008503481A (ja) | 2004-06-18 | 2008-02-07 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 悪性胸膜滲出液の処置のためのｖｅｇｆインヒビターの投与および使用の方法 |
| JP2008511337A (ja) | 2004-09-02 | 2008-04-17 | ジェネンテック・インコーポレーテッド | ヘテロ多量体分子 |
| US20080254031A1 (en) | 2004-09-09 | 2008-10-16 | Exonhit Therapeutics Sa | Tumor Specific Genes and Variant Rnas and Uses Thereof as Targets for Cancer Therapy and Diagnosis |
| JP4958555B2 (ja) | 2004-09-22 | 2012-06-20 | 協和発酵キリン株式会社 | 安定化されたヒトＩｇＧ４抗体 |
| US20060134121A1 (en) * | 2004-10-29 | 2006-06-22 | Gavin Thurston | DII4 antagonists, assays, and therapeutic methods thereof |
| US8048418B2 (en) * | 2004-10-29 | 2011-11-01 | Regeneron Pharmaceuticals, Inc. | Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists |
| US20070265246A1 (en) | 2004-11-10 | 2007-11-15 | Clevers Johannes C | Treatment of an Intestinal Adenoma and/or Adenocarcinoma by Inhibition of Notch Pathway Activation |
| EP1812064A4 (en) | 2004-11-19 | 2009-07-08 | Cornell Res Foundation Inc | USE OF VASCULAR ENDOTHEL GROWTH FACTOR RECEPTOR 1+ CELLS IN THE TREATMENT AND MONITORING OF CANCER AND SCREENING IN CHEMOTHERAPY |
| US7432107B2 (en) | 2005-01-24 | 2008-10-07 | Roche Diagnostics Operations, Inc. | Cardiac hormones for assessing cardiovascular risk |
| EP1853298A2 (en) | 2005-02-11 | 2007-11-14 | Regeneron Pharmaceuticals, Inc. | Therapeutic combination of a vegf antagonist (vegf trap) and an anti-hypertensive agent |
| DK3050963T3 (da) | 2005-03-31 | 2019-12-09 | Chugai Pharmaceutical Co Ltd | Fremgangsmåde til fremstilling af polypeptid ved regulering af arrangement |
| WO2006113665A2 (en) | 2005-04-15 | 2006-10-26 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| KR20080026562A (ko) | 2005-06-02 | 2008-03-25 | 갤럭시 바이오테크, 엘엘씨 | 항체를 이용한 뇌종양 치료 방법 |
| US7531172B2 (en) | 2005-08-12 | 2009-05-12 | Regeneron Pharmaceuticals, Inc. | Methods of treating diseases with a VEGF antagonist |
| US7906116B2 (en) | 2005-09-01 | 2011-03-15 | Parkash Gill | Methods for using and identifying modulators of Delta-like 4 |
| WO2007028110A2 (en) | 2005-09-01 | 2007-03-08 | Vasgene Therapeutics, Inc. | Methods for using and identifying modulators of delta-like 4 |
| WO2007070671A2 (en) | 2005-12-16 | 2007-06-21 | Regeneron Pharmaceuticals, Inc. | Therapeutic methods for inhibiting tumor growth with dll4 antagonists |
| WO2007098387A2 (en) | 2006-02-17 | 2007-08-30 | Gilead Colorado, Inc. | Antihypertensive therapy |
| US7354582B2 (en) | 2006-03-10 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Use of VEGF antagonists for the treatment of malignant gliomas |
| EP1999154B1 (en) | 2006-03-24 | 2012-10-24 | Merck Patent GmbH | Engineered heterodimeric protein domains |
| US20080014196A1 (en) * | 2006-06-06 | 2008-01-17 | Genentech, Inc. | Compositions and methods for modulating vascular development |
| AU2007319672B2 (en) * | 2006-06-06 | 2011-06-30 | Genentech, Inc. | Anti-DLL4 antibodies and methods using same |
| CA2655362A1 (en) * | 2006-06-13 | 2007-12-21 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
| EP2035456A1 (en) | 2006-06-22 | 2009-03-18 | Novo Nordisk A/S | Production of bispecific antibodies |
| SG174033A1 (en) | 2006-08-07 | 2011-09-29 | Regeneron Pharma | Therapeutic methods for treating vascular eye disorders with dll4 antagonists |
| ES2399075T3 (es) | 2006-08-30 | 2013-03-25 | Genentech, Inc. | Anticuerpos multiespecíficos |
| HUE028379T2 (en) | 2006-09-29 | 2016-12-28 | Oncomed Pharm Inc | Preparations and procedures for the diagnosis and treatment of cancer |
| MX2009004027A (es) | 2006-10-20 | 2009-09-28 | Schering Corp | Anticuerpos anti factor de crecimiento endotelial vascular completamente humanos y metodos de uso. |
| US20100166746A1 (en) | 2006-12-04 | 2010-07-01 | Medlmmune Way | High potency recombinant antibodies, methods for producing them and use in cancer therapy |
| RU2482877C2 (ru) | 2006-12-11 | 2013-05-27 | Дженентек, Инк. | Композиции и способы для лечения опухоли |
| NO347649B1 (no) * | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| KR20150097813A (ko) | 2006-12-19 | 2015-08-26 | 제넨테크, 인크. | 조기 종양의 치료 및 아주반트 및 네오아주반트 요법을 위한 ｖｅｇｆ－특이적 길항제 |
| EP2120996A2 (en) | 2006-12-20 | 2009-11-25 | Vasgene Therapeutics, Inc. | Methods for using and identifying modulators of delta-like 4 |
| WO2008091222A1 (en) * | 2007-01-26 | 2008-07-31 | Bioinvent International Ab | Dll4 signaling inhibitors and uses thereof |
| MX2009011898A (es) | 2007-05-04 | 2009-11-18 | Ironwood Pharmaceuticals Inc | Composiciones y metodos para tratar trastornos asociados con retencion de sal o fluido. |
| GB0709333D0 (en) | 2007-05-15 | 2007-06-20 | Smart Targeting Ltd | Binding protein |
| RU2010120674A (ru) | 2007-10-22 | 2011-11-27 | Шеринг Корпорейшн (US) | Полностью человеческие анти-vegf-антитела и способы их применения |
| CA2703154A1 (en) | 2007-10-25 | 2009-04-30 | Philogene, Inc. | Antibodies specific to pro-angiogenic isoforms of vascular endothelial growth factor (vegf) |
| WO2009075565A1 (en) | 2007-12-12 | 2009-06-18 | Erasmus University Medical Center Rotterdam | Methods for controlling vasculogenesis |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| WO2009089004A1 (en) | 2008-01-07 | 2009-07-16 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| CA2722466A1 (en) | 2008-04-29 | 2009-11-05 | Tariq Ghayur | Dual variable domain immunoglobulins and uses thereof |
| US20100260668A1 (en) | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| DK2356270T3 (da) | 2008-11-07 | 2016-12-12 | Fabrus Llc | Kombinatoriske antistofbiblioteker og anvendelser deraf |
| RS54423B1 (sr) | 2008-12-12 | 2016-04-28 | Boehringer Ingelheim International Gmbh | Anti-igf antitela |
| JP2012524083A (ja) | 2009-04-20 | 2012-10-11 | ジェネンテック， インコーポレイテッド | アジュバント癌治療 |
| WO2010124009A2 (en) | 2009-04-21 | 2010-10-28 | Schering Corporation | Fully human anti-vegf antibodies and methods of using |
| EP2424567B1 (en) | 2009-04-27 | 2018-11-21 | OncoMed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| JP2012532608A (ja) | 2009-07-08 | 2012-12-20 | アムジェン インコーポレイテッド | ＣＨ３ドメイン界面操作を通じた、安定でそして凝集しない抗体Ｆｃ分子の設計 |
| US20110172398A1 (en) | 2009-10-02 | 2011-07-14 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules for anti-angiogenesis therapy |
| ES2895226T3 (es) | 2009-10-16 | 2022-02-18 | Mereo Biopharma 5 Inc | Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensivos |
| EP2470565A4 (en) | 2009-10-23 | 2013-12-11 | Garvan Inst Med Res | MODIFIED VARIABLE DOMAIN MOLECULES AND METHODS FOR PRODUCING AND USING THE SAME |
| WO2011068840A1 (en) | 2009-12-01 | 2011-06-09 | Oncomed Pharmaceuticals, Inc. | Methods for treating cancers comprising k-ras mutations |
| WO2011100566A2 (en) | 2010-02-12 | 2011-08-18 | Oncomed Pharmaceuticals, Inc. | Methods for identifying and isolating cells expressing a polypeptide |
| RU2605928C2 (ru) | 2010-03-02 | 2016-12-27 | Эббви Инк. | Терапевтические dll4-связывающие белки |
| US20130323265A1 (en) | 2010-11-15 | 2013-12-05 | Oncomed Pharmaceuticals, Inc. | Methods for treating cancer with dll4 antagonists |
| BR112014000765A2 (pt) | 2011-07-15 | 2017-06-13 | Oncomed Pharm Inc | agentes de ligação a rspo e seus usos |
| PT2758073T (pt) | 2011-09-23 | 2019-02-01 | Oncomed Pharm Inc | Agentes de ligação a vegf/dll4 e utilizações dos mesmos |
| MX2015000565A (es) | 2012-07-13 | 2015-04-10 | Oncomed Pharm Inc | Agentes de union de proteina de r-espondina humana (rspo3) y usos de los mismos. |
| EP2914961A4 (en) | 2012-10-31 | 2016-04-20 | Oncomed Pharm Inc | METHODS AND MONITORING A TREATMENT BY AN ANTAGONIST OF DLL4 |
-
2007
- 2007-09-28 HU HUE07838966A patent/HUE028379T2/en unknown
- 2007-09-28 NZ NZ576404A patent/NZ576404A/en unknown
- 2007-09-28 MX MX2009003229A patent/MX2009003229A/es active IP Right Grant
- 2007-09-28 EP EP12185260A patent/EP2562188A3/en not_active Withdrawn
- 2007-09-28 AU AU2007305443A patent/AU2007305443B2/en active Active
- 2007-09-28 US US11/905,392 patent/US7750124B2/en active Active
- 2007-09-28 EP EP17205290.4A patent/EP3357932A1/en not_active Withdrawn
- 2007-09-28 KR KR1020097008735A patent/KR101477824B1/ko not_active Expired - Fee Related
- 2007-09-28 PL PL07838966T patent/PL2066694T3/pl unknown
- 2007-09-28 RS RS20160035A patent/RS54452B1/sr unknown
- 2007-09-28 EA EA200970335A patent/EA018260B1/ru not_active IP Right Cessation
- 2007-09-28 DK DK07838966.5T patent/DK2066694T3/en active
- 2007-09-28 ME MEP-2016-8A patent/ME02371B/me unknown
- 2007-09-28 JP JP2009530419A patent/JP5535633B2/ja not_active Expired - Fee Related
- 2007-09-28 EP EP07838966.5A patent/EP2066694B1/en active Active
- 2007-09-28 CA CA2664738A patent/CA2664738C/en active Active
- 2007-09-28 SI SI200731729T patent/SI2066694T1/sl unknown
- 2007-09-28 BR BRPI0717431-4A patent/BRPI0717431A2/pt not_active IP Right Cessation
- 2007-09-28 WO PCT/US2007/020889 patent/WO2008042236A2/en not_active Ceased
- 2007-09-28 ES ES07838966.5T patent/ES2557953T3/es active Active
- 2007-09-28 HR HRP20160082TT patent/HRP20160082T1/hr unknown
- 2007-09-28 PT PT78389665T patent/PT2066694E/pt unknown
-
2009
- 2009-03-06 ZA ZA2009/01615A patent/ZA200901615B/en unknown
- 2009-03-18 CR CR10667A patent/CR10667A/es not_active Application Discontinuation
- 2009-03-19 IL IL197721A patent/IL197721A/en active IP Right Grant
- 2009-03-26 CO CO09031240A patent/CO6180466A2/es active IP Right Grant
- 2009-04-22 MA MA31810A patent/MA30808B1/fr unknown
- 2009-04-24 NO NO20091635A patent/NO20091635L/no not_active Application Discontinuation
-
2010
- 2010-05-18 US US12/782,429 patent/US9376497B2/en active Active
-
2013
- 2013-03-14 US US13/826,103 patent/US9228020B2/en active Active
-
2014
- 2014-03-06 JP JP2014043403A patent/JP5997194B2/ja not_active Expired - Fee Related
-
2016
- 2016-01-21 CY CY20161100065T patent/CY1117154T1/el unknown
- 2016-05-27 US US15/167,510 patent/US20160367667A1/en not_active Abandoned
- 2016-08-25 JP JP2016164264A patent/JP2017002076A/ja active Pending
-
2018
- 2018-08-24 US US16/111,841 patent/US20190060453A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014158469A5 (enExample) | ||
| ME02371B (me) | Sastojci i postupci za dijagnstikovanje i tretman raka | |
| JP2018508483A5 (enExample) | ||
| JP2018503365A5 (enExample) | ||
| JP2018527919A5 (enExample) | ||
| JP2020528750A5 (enExample) | ||
| JP2017514461A5 (enExample) | ||
| JP2017507900A5 (enExample) | ||
| JP2010504755A5 (enExample) | ||
| RU2016137110A (ru) | Антитела к компоненту комплемента с5 | |
| JP2015529641A5 (enExample) | ||
| JP2013502913A5 (enExample) | ||
| JP2014511179A5 (enExample) | ||
| HRP20221226T1 (hr) | Protutijela protiv pd-1 i postupci njihove upotrebe | |
| CN109311978B (zh) | Dsg2单克隆抗体和其用途 | |
| JP2019526622A5 (enExample) | ||
| JP2018534933A5 (enExample) | ||
| JP2017535257A5 (enExample) | ||
| RU2013102225A (ru) | АНТИТЕЛА ПРОТИВ Axl И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| RU2017119543A (ru) | Анти-tim3 антитела и способы их применения | |
| JP2017506217A5 (enExample) | ||
| JP2011514150A5 (enExample) | ||
| JP2017529838A5 (enExample) | ||
| JP2013538553A5 (enExample) | ||
| JP2015500207A5 (enExample) |